Dexlansoprazole paten?

Do you want patent status for dexlansoprazole in a specific country (e.g., US, EU, India)? I can help with exact patent numbers and expiry dates if you tell me the jurisdiction.

What I can tell you right away:
- Dexlansoprazole is the R-enantiomer of lansoprazole and is sold as Dexilant. Takeda originally held the key patent family covering the compound, the dual-delayed-release formulation, and uses (treating GERD, etc.).
- The patent coverage includes:
- Composition-of-matter (the dexlansoprazole compound and its salts).
- Formulation patents for the dual-delayed-release capsule.
- Method-of-use patents (treatment indications such as GERD/erosive esophagitis).
- Related patents on salts, polymorphs, manufacturing processes, and certain dosing/regimen specifics.
- Patent expiry is jurisdiction-specific and can be affected by term adjustments and pediatric exclusivity. In many markets the core patents have expired or are nearing expiry, but there may be additional active patents on specific formulations, salts, or manufacturing methods.

How to check precisely:
- US: Use the FDA Orange Book (Patents and Exclusivity) for Dexilant (dexlansoprazole). It lists patent numbers and expiration dates.
- Global: Look up the patent family on Google Patents or Espacenet (search "dexlansoprazole" and filter by country). Also check WIPO Patentscope for international families.
- If you share a country, I can guide you to the exact patent numbers and give you a summary of their status (active, expired, under litigation, etc.).

If you want, tell me the country and I’ll pull (or guide you to) the current patent numbers and expiration dates for that jurisdiction.